5124-25-4 Usage
Description
Disperse Yellow Se-Fl is a synthetic disperse dye compound that is characterized by its brilliant yellow color. It is specifically designed for the dyeing and printing of polyester fibers, offering excellent performance in terms of ironing, light, perspiration, and washing fastness.
Uses
Used in Textile Industry:
Disperse Yellow Se-Fl is used as a dye for polyester fiber dyeing and printing. It provides excellent fastness properties, making it a preferred choice for various textile applications.
The dye exhibits the following fastness ratings according to the American Association of Textile Chemists and Colorists (AATCC) standards:
1. Ironing Fastness: 5
2. Light Fastness: 5
3. Perspiration Fastness: 5
4. Washing Fastness (Fading): 5
5. Washing Fastness (Staining): 5
These ratings indicate that Disperse Yellow Se-Fl offers high resistance to fading and staining under various conditions, making it suitable for use in the production of durable and long-lasting textiles.
Preparation
2-Nitro-N-isobutylbenzenesulfonamide and Aniline condensation
Flammability and Explosibility
Notclassified
Standard
Ironing Fastness
Fading
Stain
Check Digit Verification of cas no
The CAS Registry Mumber 5124-25-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,1,2 and 4 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 5124-25:
(6*5)+(5*1)+(4*2)+(3*4)+(2*2)+(1*5)=64
64 % 10 = 4
So 5124-25-4 is a valid CAS Registry Number.
InChI:InChI=1/C18H15N3O4S/c22-21(23)18-13-16(26(24,25)20-15-9-5-2-6-10-15)11-12-17(18)19-14-7-3-1-4-8-14/h1-13,19-20H
5124-25-4Relevant articles and documents
THERAPEUTIC COMPOUNDS AND COMPOSITIONS
-
Page/Page column 189; 190, (2014/05/07)
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
